Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18577442 | 1.00 | POLB (0.61) | POLBLTA4HHTR6CHRNA3 | |
| SCHEMBL1443794 | 1.00 | POLB (0.61) | POLBLTA4HHTR6CHRNA3 | |
| Hydrochloric Acid SCHEMBL7278039 | 0.98 | POLB (0.59) | POLBLTA4HHTR6 | |
| SCHEMBL18577477 | 0.95 | POLB (0.69) | POLBLTA4H | |
| SCHEMBL18577474 | 0.95 | POLB (0.69) | POLBLTA4H | |
| SCHEMBL11474398 | 0.93 | POLB (0.67) | POLBLTA4H | |
| Hydrochloric Acid SCHEMBL7248436 | 0.93 | POLB (0.67) | POLBLTA4H | |
| Hydrochloric Acid SCHEMBL11472694 | 0.91 | POLB (0.65) | POLBLTA4H | |
| SCHEMBL21565752 | 0.86 | POLB (0.47) | POLBLTA4H | |
| SCHEMBL10132251 | 0.81 | POLB (0.61) | POLBLTA4HHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920771-A | Novel synthesis process of intermediate of novel oral medicine for overactive bladder | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | POLB 3807/4885LTA4H 1608/4885HTR6 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.